drugset / Trial / NCT07456059

A Study to Evaluate EDG-7500 in Caucasian and Japanese Adults

NCT07456059 ↗

Phase 1 Not yet recruiting 24 enrolled Edgewise Therapeutics, Inc.
NaParallel-groupOpen-labelBasic science

Summary

The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after single and multiple doses in Japanese and Caucasian adults. The safety of EDG-7500 in these adult participants will also be evaluated in this study.

Timeline

Start
2026-03
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject EDG-7500 Unknown — Oral

Indications

No indication recorded.